MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Brokerages

Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received a consensus recommendation of "Hold" from the nine analysts that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.43.

A number of analysts have weighed in on the company. StockNews.com lowered MacroGenics from a "buy" rating to a "hold" rating in a report on Friday, March 21st. HC Wainwright dropped their price target on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 25th.

Institutional Trading of MacroGenics

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC grew its stake in shares of MacroGenics by 104.5% in the fourth quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company's stock worth $112,000 after acquiring an additional 17,577 shares in the last quarter. Barclays PLC raised its stake in shares of MacroGenics by 97.1% during the third quarter. Barclays PLC now owns 98,753 shares of the biopharmaceutical company's stock worth $325,000 after purchasing an additional 48,639 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of MacroGenics by 7.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 527,185 shares of the biopharmaceutical company's stock worth $1,713,000 after acquiring an additional 34,420 shares during the period. Wellington Management Group LLP lifted its holdings in shares of MacroGenics by 5.4% in the 4th quarter. Wellington Management Group LLP now owns 323,857 shares of the biopharmaceutical company's stock valued at $1,053,000 after buying an additional 16,717 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of MacroGenics by 68.3% during the 4th quarter. JPMorgan Chase & Co. now owns 546,807 shares of the biopharmaceutical company's stock worth $1,777,000 after purchasing an additional 221,905 shares during the period. Hedge funds and other institutional investors own 96.89% of the company's stock.

MacroGenics Stock Performance

Shares of MacroGenics stock traded down $0.06 during trading hours on Friday, hitting $1.53. The company's stock had a trading volume of 24,330 shares, compared to its average volume of 963,925. MacroGenics has a 12-month low of $0.99 and a 12-month high of $5.77. The business has a 50 day moving average price of $1.62 and a two-hundred day moving average price of $2.65. The company has a market cap of $96.46 million, a PE ratio of -0.97 and a beta of 2.20.

MacroGenics (NASDAQ:MGNX - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The company had revenue of $49.40 million for the quarter, compared to the consensus estimate of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. As a group, research analysts anticipate that MacroGenics will post -1.06 earnings per share for the current year.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.